Press Releases Items Per Page 102550 Year None2020201920182017201620152014 05-14-2020 Daré Bioscience Reports First Quarter 2020 Financial Results and Provides Company Update 05-11-2020 Daré Bioscience and Health Decisions Form Strategic Partnership to Accelerate the Development of Daré’s Novel Pipeline of Women’s Health Programs 05-07-2020 Daré Bioscience to Host First Quarter 2020 Financial Results and Company Update Conference Call and Webcast on May 14, 2020 04-28-2020 Daré Bioscience CEO to Participate in Maxim Group’s Infectious Disease Virtual Conference 04-23-2020 Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC 04-01-2020 Daré Bioscience Receives Third Notice of Award from National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development for the Development of Ovaprene® 03-30-2020 Daré Bioscience Reports 2019 Financial Results and Provides a Company Update 03-24-2020 Daré Bioscience to Host Fourth Quarter and Full-year 2019 Financial Results and Company Update Conference Call and Webcast on March 30, 2020 03-10-2020 Daré Bioscience Receives FDA Fast Track Designation for DARE-BV1 for the Treatment of Bacterial Vaginosis 03-09-2020 Daré Bioscience Presents Positive Sildenafil Cream, 3.6% Data Supporting Further Development for the Treatment of Female Sexual Arousal Disorder Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 16
05-11-2020 Daré Bioscience and Health Decisions Form Strategic Partnership to Accelerate the Development of Daré’s Novel Pipeline of Women’s Health Programs
05-07-2020 Daré Bioscience to Host First Quarter 2020 Financial Results and Company Update Conference Call and Webcast on May 14, 2020
04-23-2020 Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC
04-01-2020 Daré Bioscience Receives Third Notice of Award from National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development for the Development of Ovaprene®
03-24-2020 Daré Bioscience to Host Fourth Quarter and Full-year 2019 Financial Results and Company Update Conference Call and Webcast on March 30, 2020
03-10-2020 Daré Bioscience Receives FDA Fast Track Designation for DARE-BV1 for the Treatment of Bacterial Vaginosis
03-09-2020 Daré Bioscience Presents Positive Sildenafil Cream, 3.6% Data Supporting Further Development for the Treatment of Female Sexual Arousal Disorder
